[TLR9 and HBD-2 gene expression by conjunctival and corneal cells in children with dendriform herpetic keratitis].

The current views of the role of innate immunity in protecting the organ of vision from viral infection offer scope for a search for new approaches to diagnosing and treating viral keratitis. TLR9 and HBD-2 gene expression in the conjunctiva and cornea was studied in children with dendriform herpetic keratitis. The latter showed a significant (more than 20-fold) increase in TLR9 gene expression as compared in healthy children. Conventional antiviral therapy for herpetic keratitis resulted in a significant decrease in the level of TLR9 gene expression (by more than two orders of magnitude). The use of the immunomodulator Superlymph in complex treatment normalized the level of TLR9 gene expression in the conjunctiva and cornea; moreover, there was a rapid relief of inflammation signs, an increase in visual acuity, and a reduction in the duration of treatment in patients with herpetic keratitis.

[Cytokine therapy in the regulation of corneal reparative processes: an experimental and clinical study].

Cytokine monotherapy with Superlymph used in combination with the keratoprotector Applicoll in the treatment of superficial corneal layer defect resulted in rapidly alleviated inflammatory reactions, accelerated reparative processes, more qualitative epithelial defect recovery, by forming a finer scar, without opacity whereas the traditional treatment led to long-term healing and keratoleukoma in an experiment. The use of cytokine therapy with Superlymph in the complex treatment of corneal injuries and inflammation in children promoted a prompt and stable arrest of a local inflammatory process, accelerated epithelization, reduced opacity intensity, higher visual acuity, and shorter treatment.